new glp-1 drug Drugs from the Gray Market Swiss Re says GLP-1 drugs
Description
doi: 10.1007/s004419900093
Alfaris said gastrointestinal adverse events were more common with orforglipron than placebo and were consistent with those seen in other incretin-based drugs
First in man studies reported in December 1987 by Kreymann and Bloom (26) rapidly established the insulinotropic actions of GLP-1(7-36) amide in human subjects
Consistent with earlier studies, side effects emerged as the most commonly cited reason for discontinuation, regardless of medication indication
